📣🎉New pooled library! This screening library from George Church's lab contains all possible single codon substitutions, deletions, and insertions in the AAV2 cap gene.
https://t.co/krbqJ7ywNU
@Addgene Honored to have one of our plasmids posted as Addgene plasmid of the day! BI28 is a highly efficient capsid for CNS transduction in all strains of mice. It was engineered by reprogramming AAV9 to bind LY6C1 in vitro.
We have released a preprint “Targeting AAV vectors to the CNS via de novo engineered capsid-receptor interactions”.
We developed gene delivery vectors with known mechanisms of action & predictable tropisms by targeting AAVs to specific proteins.
https://t.co/ObDwFiOoCC
We believe this strategy will accelerate the development of AAV gene delivery vectors that bind defined targets on different disease-relevant cell types with high specificity and across species to enable translation from preclinical models to investigational human gene therapies.
Early-career scientists: We want to fund your pilot studies in #genetherapy & #celltherapy!
ASGCT Members can apply for one of six $100,000 #CareerDevelopment awards by Aug. 1. Learn more and apply today! https://t.co/NYpOcSnd8S
ICYMI: Read all about Andy’s ‘10 amazing story - from successful robotics engineer to a machine learning scientist working on gene therapy at the @broadinstitute in @DevermanLab. https://t.co/EYOu778PdJ
Come see how we are conceptually upending protein evolution approaches by building a machine learning-driven atlas to efficiently identify AAV capsids with multiple desired traits (improved tropisms + manufacturability).
Talk abstract 1201
May 19, 11:45am
@ASGCTherapy#ASGCT22
Ken Chan from the Deverman lab @broadinstitute@StanleyCenter is presenting data on several AAVs that can efficiently deliver genes to the brain and spinal cord.
Our talk is on May 19, 10:45am
@ASGCTherapy#ASGCT22
Abstract 1197